Literature DB >> 9836710

Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system.

T Yajima1, A Yagihashi, H Kameshima, D Kobayashi, D Furuya, K Hirata, N Watanabe.   

Abstract

We established the validity of a quantitative reverse transcription (RT)-PCR assay for the RNA component of human telomerase (hTR), using the TaqMan fluorogenic detection system. Using this assay, we quantified hTR expression in two human pancreatic cancer cell lines, ASPC-1 and MIAPaCa-2. Our results indicated that hTR expression in MIAPaCa-2 was 1.99-fold higher than that in ASPC-1 cells. This TaqMan RT-PCR assay appears to be useful in determining the amount of hTR in clinical specimens.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9836710

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


  18 in total

1.  Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Authors:  R V Lord; D Salonga; K D Danenberg; J H Peters; T R DeMeester; J M Park; J Johansson; K A Skinner; P Chandrasoma; S R DeMeester; C G Bremner; P I Tsai; P V Danenberg
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

2.  Changes in expression of GABAA alpha4 subunit mRNA in the brain under anesthesia induced by volatile and intravenous anesthetics.

Authors:  Shusuke Sekine; Shohei Matsumoto; Atsushi Issiki; Taiko Kitamura; Jinzo Yamada; Yasuo Watanabe
Journal:  Neurochem Res       Date:  2006-05-03       Impact factor: 3.996

3.  Human beta-defensin-3 induction in H. pylori-infected gastric mucosal tissues.

Authors:  K Kawauchi; A Yagihashi; N Tsuji; N Uehara; D Furuya; D Kobayashi; N Watanabe
Journal:  World J Gastroenterol       Date:  2006-09-28       Impact factor: 5.742

4.  Detection of cancer cells and gene expression of cytokines in the peritoneal cavity in patients with gastric cancer.

Authors:  Youji Fukumoto; Masahide Ikeguchi; Sachiko Matsumoto; Masashi Inoue; Tomohiro Osaki; Kenji Fukuda; Hiroaki Saito; Shigeru Tatebe; Shun-Ichi Tsujitani
Journal:  Gastric Cancer       Date:  2006-11-24       Impact factor: 7.370

5.  Quantitative reverse transcriptase polymerase chain reaction analysis for KiSS-1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in hepatocellular carcinoma.

Authors:  Masahide Ikeguchi; Yasuaki Hirooka; Nobuaki Kaibara
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-25       Impact factor: 4.553

6.  Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome.

Authors:  Anna Marrone; Amanda Walne; Hannah Tamary; Yuka Masunari; Michael Kirwan; Richard Beswick; Tom Vulliamy; Inderjeet Dokal
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

7.  A novel mechanism of late gene silencing drives SV40 transformation of human mesothelial cells.

Authors:  Michele Carbone; Antonio Pannuti; Lei Zhang; Joseph R Testa; Maurizio Bocchetta
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

8.  Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10.

Authors:  Amanda J Walne; Tom Vulliamy; Anna Marrone; Richard Beswick; Michael Kirwan; Yuka Masunari; Fat-Hia Al-Qurashi; Mahmoud Aljurf; Inderjeet Dokal
Journal:  Hum Mol Genet       Date:  2007-05-16       Impact factor: 6.150

9.  survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma.

Authors:  M Ikeguchi; N Kaibara
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

10.  Telomerase reverse transcriptase and telomeric-repeat binding factor protein 1 as regulators of telomerase activity in pancreatic cancer cells.

Authors:  T Yajima; A Yagihashi; H Kameshima; D Kobayashi; K Hirata; N Watanabe
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.